This site is intended for Healthcare professionals only.
×

Mylan, TB Alliance to commercialize Pretomanid to treat TB


Mylan, TB Alliance to commercialize Pretomanid to treat TB

TB Alliance began preclinical development of pretomanid in 2002, and it has since studied pretomanid in 20 clinical trials alone or in combination with other anti-TB drugs. 

New Delhi: Pharmaceutical company, Mylan N.V and Non-profit drug developer, TB Alliance recently announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).

Pretomanid is a new chemical entity and a member of a class of compounds known as nitroimidazooxazines. TB Alliance began preclinical development of pretomanid in 2002, and it has since studied pretomanid in 20 clinical trials alone or in combination with other anti-TB drugs. Pretomanid has been administered in a clinical trial setting to more than 1,200 people in 14 countries.

The two pretomanid-based regimens under development include;

  • For XDR-TB and MDR-TB that is treatment-intolerant or non-responsive: All oral, six- to nine-month treatment regimen consisting of bedaquiline, pretomanid and linezolid (“BPaL” regimen)
  • For DS-TB and MDR-TB: All oral, four- and six-month treatments, respectively, consisting of bedaquiline, pretomanid, moxifloxacin and pyrazinamide (“BPaMZ” regimen)

As part of the BPaL regimen, TB Alliance has granted a license to Mylan to manufacture and commercialize pretomanid, pending regulatory approval, for XDR-TB and treatment-intolerant or non-responsive MDR-TB.

As part of the BPaMZ regimen, TB Alliance has licensed pretomanid to Mylan for DS- and MDR-TB, and has granted a sublicense for bedaquiline to Mylan, for its development and commercialization for use in DS-TB only, under its license agreement with Janssen Pharmaceutical N.V.

Commenting on the move, Mylan CEO Heather Bresch added, “For more than a decade, Mylan has led the charge in accelerating access to high quality and affordable antiretrovirals for people living with HIV all over the world. We look forward to collaborating with TB Alliance to bring that same level of commitment and innovation to the millions of people suffering from tuberculosis, many of whom also have HIV. The drug regimens under development represent an important step in transforming the TB treatment landscape.”

Also Read: Mylan launches Advair generic at 70 percent discount in US



Source: self
0 comment(s) on Mylan, TB Alliance to commercialize Pretomanid to treat TB

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted